Why this innovation?

The latest advances in Blow-Fill-Seal (BFS) technology pave the way for a new generation of pre-filled injectable devices, capable of combining high levels of sterility, large-scale production and very low manufacturing costs.. This development also helps meet the growing needs of market stakeholders and patients, who are seeking simpler, safer, and more accessible injection solutions.

→

A need for simpler and safer injection solutions for healthcare professionals.

→

A need to reduce costs and improve access to vaccines in developing countries.

→

A demand for devices without supply chain disruption and suitable for high-speed production.

→

Growing demand for pre-filled, sterile, and ready-to-use injectable systems.

The solution: what it changes

Euroject® is a pre-filled single-dose injectable device that is made using BFS technology on a high-speed rotary machine. It combines sterility, ease of use and large-scale production.

What makes it unique

  • Blow-Fill-Seal technology: advanced aseptic process ensuring a high level of sterility.

  • Mass production: up to 1 billion doses/year in a dedicated BSL2 (biosafety level) facility.

  • Competitive pricing

  • Very low production cost, thanks to BFS throughput.

  • No supply chain disruption

  • Easier access to new markets (developing countries)

Benefits for (healthcare professionals / patients)

Simple and secure administration that is perfectly adapted to daily practices, with a pre-filled single-dose device that limits handling and reduces the risk of error. Sterility is guaranteed right up to the moment of injection.

According to a study conducted among healthcare professionals (2021-2022):

73%

consider the device is time-saving

74%

consider the device is easy to use

73%

consider the device is easy to store

80%

consider Euroject® is innovative

Client benefits

transport

Distribution

  • Easier access to new markets, such as developing countries.

  • Sterile single-dose format allowing a simplified supply chain

  • Supply reliability thanks to very high capacity and robust production.

Ligne BFS Amiens

Manufacturing

  • Competitive costs thanks to the high-speed BFS process.

  • Very high industrial capacity: up to 1 billion doses per year.

  • A dedicated BSL2 facility in Amiens for biological products and vaccines.

  • Royalty-free technology, adaptable to different product needs.

Manufacturing sites

All our French sites are subject to inspections by European authorities, allowing us to manufacture products for European markets. The Coutances and Amiens sites (France) are regularly inspected by the ANSM (French National Agency for the Safety of Medicines and Health Products), the FDA (U.S. Food and Drug Administration), the KFDA (Korean Food and Drug Administration), and other international health authorities.

Our injectables team

Alexandre FONTAYNE

CSO

Marlish RATNAKUMAR

Business Development Manager

Do you have any questions? - Consult our Euroject FAQ

Yes, in many cases: it is a single-dose, ready-to-inject device. It offers cost reduction and reduced handling and ensures efficient volume delivery (0.47–0.49 mL delivered according to tests). It also addresses vaccine equity issues: no glass, simplified logistics, and greater facility for healthcare providers.

Yes. Despite the use of heat during plastic molding, the Blow-Fill-Seal (BFS) process is very fast, which limits exposure and preserves the integrity of heat-sensitive formulations. Clinical studies have shown that BFS-packaged vaccines, such as flu vaccines or GSK’s Rotarix®, maintain their efficacy and stability, equivalent to those obtained in glass vials. BFS is therefore a safe and innovative option for injectable or oral vaccines and biological products. The very rapid cycle of BFS limits thermal exposure (<40°C over the majority of the volume) and preserves the integrity of biological products, including recombinant protein vaccines. This has been demonstrated by several studies (GSK, MedImmune, Unither).